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Purpose
Capturing patient-reported outcome data is important for evaluating the overall clinical benefits of
new cancer therapeutics. We assessed self-reported symptoms of advanced non–small-cell lung
cancer in patients treated with osimertinib or chemotherapy in the AURA3 phase III trial.
Patients and Methods
Patients completed the European Organisation for Research and Treatment of Cancer 13-item
Quality of Life Questionnaire-Lung Cancer Module (EORTC QLQ-LC13) questionnaire on disease-
specific symptoms and the EORTC 30-item Core Quality of Life Questionnaire (EORTCQLC-C30) on
general cancer symptoms, functioning, global health status/quality of life. We assessed differences
between treatments in time to deterioration of individual symptoms and odds of improvement (a
deterioration or improvement was defined as a change in score from baseline of$ 10). Hazard ratios
(HRs) were calculated using a log-rank test stratified by ethnicity; odds ratios (ORs) were assessed
using logistic regression adjusted for ethnicity.
Results
At baseline, the questionnaires were completed by 82% to 88% of patients, and 30% to 70% had
individual key symptoms. Time to deterioration was longer with osimertinib thanwith chemotherapy
for cough (HR, 0.74; 95% CI, 0.53 to 1.05), chest pain (HR, 0.52; 95% CI, 0.37 to 0.73), and dyspnea
(HR, 0.42; 95%CI, 0.31 to 0.58). The proportion of symptomatic patients with improvement in global
health status/quality of life was higher with osimertinib (80 [37%] of 215) than with chemotherapy
(23 [22%] of 105; OR, 2.11; 95%CI, 1.24 to 3.67; P= .007). Proportions were also higher for appetite
loss (OR, 2.50; 95% CI, 1.31 to 4.84) and fatigue (OR, 1.96; 95% CI, 1.20 to 3.22).
Conclusion
Time to deterioration of key symptoms was longer with osimertinib than with chemotherapy, and
a higher proportion of patients had improvement in global health status/quality of life, demonstrating
improved patient outcomes with osimertinib.
J Clin Oncol 36:1853-1860. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Epidermal growth factor receptor (EGFR)–mutated
non–small-cell lung cancer (NSCLC) is a distinct
subtype of lung cancer characterized by a high re-
sponse rate when treated with EGFR tyrosine kinase
inhibitors (TKIs).1 A meta-analysis has shown that
in treatment-na¨ıve patients, erlotinib and gefitinib
(first-generation TKIs) are associated with a median
progression-free survival (PFS) of 11.0 months
compared with 5.6 months for those who received
chemotherapy.2 In addition, afatinib and dacomiti-
nib (second-generation TKIs) have been associated
with improved PFS compared with chemotherapy3,4
and gefitinib.5,6 Despite an initial response, most
patients will ultimately develop resistance to TKIs,
with approximately 60% developing an additional
EGFR T790M mutation.7-9
Osimertinib is a third-generation, irrevers-
ible EGFR-TKI that is selective for both EGFR-
sensitizing and T790M-resistance mutations.10-13
AURA3 (NCT02151981; AZD9291 Versus Platinum-
Based Doublet-Chemotherapy in Locally Ad-
vanced or Metastatic Non–Small Cell Lung
Cancer) was a randomized, phase III trial that
investigated the superiority of osimertinib over
platinum-pemetrexed chemotherapy in patients with
confirmed T790M-positive NSCLC that had relapsed
after first-line EGFR-TKI therapy.14,15 In this trial,
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osimertinib significantly improved PFS over chemotherapy (hazard
ratio [HR], 0.30; 95% CI, 0.23 to 0.41).14 In another recently reported
study, osimertinibwas shown to significantly improve PFS over gefitinib
or erlotinib in treatment-na¨ıve patients with advanced EGFR-mutant
disease.16
Despite this recent therapeutic advancement, metastatic EGFR-
mutated NSCLC remains incurable in the majority of patients, and
thus treatment is aimed at palliation.17 Furthermore, lung cancer is
characterized by high symptom burden,18 and key symptoms
according to patient reports are cough, dyspnea, chest pain, fatigue,
and appetite loss.19-22 Fatigue, appetite loss, dyspnea, and pain are
experienced by at least 90% of patients and have a significant negative
effect on disease-specific health-related quality of life (HRQoL).21,23
Knowledge of the effect of new therapeutics on patient experience is
useful and, in combination with survival data, could provide vital
information to help physicians and patients in making treatment
decisions.24,25 Indeed, it is recommended that patient-reported
symptoms and HRQoL are assessed in all prospective clinical
comparative effectiveness research.26
PFS is a commonly used primary efficacy end point in on-
cology trials and is widely accepted by regulators as a surrogate for
treatment efficacy.27,28 Improvement in PFS is important in in-
curable cancer but is not the only measure of clinical benefit and
thus may be supplemented with improvement in patient-relevant
symptoms.25 PFS alone does not directly measure how a patient
feels, functions, or survives,25 but it is increasingly being used as
a primary end point in recent clinical trials of advanced NSCLC.29
Conversely, data from patient-reported outcomes (PROs) provide
patients’ perspectives of their symptoms, functional activities, and
HRQoL.30 These self-reported symptoms and measures of func-
tioning reflect both tumor response and control and treatment-
related toxicities. Given that past clinical trials of first-line EGFR
TKIs compared with chemotherapy could not demonstrate overall
survival benefit,2,31 documenting PRO improvement can further
complement PFS prolongation, substantiate the clinical mean-
ingfulness of PFS, and help assess the net overall clinical benefit of
a new therapeutic.
In this article, we report PROs from AURA3, which were
a secondary outcome of this trial. The patient-reported symptoms,
functioning, health status, and quality of life (QoL) were assessed by
using two self-administered cancer-specific questionnaires developed
by the European Organisation for Research and Treatment of Cancer
(EORTC): the 30-item Core Quality of Life Questionnaire (QLQ-
C30)32 and the 13-item Quality of Life Questionnaire-Lung Cancer
Module (QLQ-LC13).33 These instruments have demonstrated
reliability and validity, are commonly used in clinical trials, and
provide complementary and corroborative information about
HRQoL in advanced lung cancer. The QLQ-LC13 questionnaire
specifically captures the key lung cancer–associated symptoms
that are predominant and burdensome, particularly in this pa-
tient population. We aimed to assess prespecified self-reported
symptoms and functioning of patients treated with osimertinib or
platinum-based doublet chemotherapy. We investigated whether
NSCLC–specific symptoms deteriorate more slowly and whether
a greater proportion of symptomatic patients will have an im-
provement in symptoms, functioning, and global health status/
quality of life when treated with osimertinib compared with
chemotherapy.
PATIENTS AND METHODS
Study Design
The details of the AURA3 trial design and the PFS efficacy results are
published elsewhere.14,15
PRO Assessments
The EORTC QLQ-C30 is a robust HRQoL instrument that gives
similar results when used in different countries and in different translated
versions and is considered to be suitable for use in multinational clinical
trials.34-36 The QLQ-C30 comprises questions on general cancer symp-
toms, functioning, global health status/quality of life and financial diffi-
culties. It incorporates both multi-item scales and single-item measures,
including one global health status/quality of life scale, five functional scales,
three symptoms scales, and six single items. The 13-item QLQ-LC13
comprises questions on disease-specific symptoms. It incorporates one
multi-item scale to assess dyspnea, and a series of single items to assess pain,
coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and
hemoptysis. The QLQ-C30 was tested in interviews with patients with lung
cancer during development of the disease-specific QLQ-LC13 module.37
All scales and single-item measures range in score from 0 to 100. The
principle for scoring these scales is the same in all cases and involves
calculating the average of the items that contribute to the scale (the raw
score) and then using a linear transformation to standardize the raw score;
scores therefore range from 0 to 100, with higher scores representing
a better level of functioning or QoL or a worse level of symptoms. We defined
symptomatic patients as those having a baseline symptom score $ 10.
The QLQ-LC13 questionnaire was administered at baseline, then
once per week for 6 weeks, then once every 3 weeks up to the end of the
study and at progression. The QLQ-C30 was administered at baseline, then
once every 6 weeks up to the end of the study and at progression.
Assessments and Statistical Analysis
Multifaceted assessments were performed to capture various aspects
of PROs. First, we examined the odds of improvement in key symptoms
and functioning domains for symptomatic patients at baseline between
treatment arms. The prespecified key symptoms of importance in ad-
vanced NSCLC were cough, chest pain, dyspnea, fatigue, and appetite
loss.19-21 The odds of improvement in symptoms and functioning domains
were computed by using a mixed-effect logistic regression model for
longitudinal binary outcome of improvement from baseline (decrease in
symptom score from baseline of$ 10 or increase in functional score from
baseline of $ 10) versus no improvement. Each longitudinal analysis
included treatment arm, time (visit number) variable, baseline score,
treatment-by-time interaction, and ethnicity (Asian or non-Asian) as
covariates. The analyses for each item used all data up to disease pro-
gression and beyond. The symptom improvement rate was defined as the
number (%) of patients with two consecutive assessments at least 18 days
apart, which showed a clinically meaningful improvement (a decrease from
baseline score$ 10 for EORTCQLQ-LC13 or QLQ-C30 scales or items) in
that symptom from baseline.
Second, treatment arms were also compared for differences in time to
deterioration of symptoms and functioning domains over the course of the
study for all patients with baseline readings. A deterioration or im-
provement in a particular symptom was defined as a change (increase or
decrease) in score from baseline of $ 10, which corresponded to the
minimal threshold for a moderate change.38 HRs and 95% CIs were
calculated using a log-rank test stratified by ethnicity (Asian or non-Asian).
Finally, the mean continuous differences in symptoms and func-
tioning domains were calculated using the mixed-effect model repeat
measurement (average over 6 months). Each longitudinal analysis included
treatment arm, time variable, baseline symptom/functioning domains
score, and treatment-by-time interaction as covariates. Patient was defined
as a random variable, and the covariance structure was assumed to be
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unstructured. Estimates of the least-squares means for treatment effects
within and between treatment groups were reported with corresponding
95% CIs. The analyses for each item included postbaseline data up to week
24 and excluded assessments completed outside this prespecified time range.
Sensitivity Analysis
Our main analysis examined all PRO data collected from baseline to
after progression. In the sensitivity analysis, we limited our assessment
from baseline to disease progression to evaluate whether these subset data
were consistent with our overall analyses.
The trial sponsor collected and analyzed the data, and the lead in-
vestigators had full access to the data. For all analyses, P values are provided
to aid interpretation but must be interpreted conservatively, given the
multiple scales, time points, and hypotheses. The data cutoff date was April
15, 2016.
RESULTS
Completion of PRO Instrument
A total of 279 patients were allocated to osimertinib and 140 to
chemotherapy (Fig 1). At baseline, 82.4% of patients who received
osimertinib and 82.9% who received chemotherapy completed the
QLQ-LC13; 88.2% and 82.8%, respectively, completed the QLQ-
C30 (Fig 2). At 3 months, 80.7% of patients who received osi-
mertinib and 73.4% who received chemotherapy completed the
QLQ-LC13; 84.4% and 72.8% of patients receiving osimertinib and
chemotherapy, respectively, completed the QLQ-C30. At 1 year,
questionnaire completion rates were at least 60% for both treat-
ment arms.
Baseline PRO Data
The baseline scores were relatively well balanced between
treatment arms (Table 1). Apart from chest pain and appetite loss,
approximately 50% to 70% of patients experienced one or more of
the key lung cancer symptoms.
Odds of Improvements in PRO Symptoms and
Functioning
The symptom improvement rate was enhanced with osi-
mertinib compared with chemotherapy for the five prespecified key
symptoms; the greatest improvements with osimertinib were seen in
dyspnea, fatigue, and appetite loss (Fig 3). A higher proportion of
patients had improvement in functioning domains with osimertinib
than with chemotherapy, particularly for the physical, role, and social
functioning and global health status/quality of life domains (Appendix
Fig A1, online only). The corresponding data for improvement in the
remaining QLQ-LC13 and QLQ-C30 symptoms are shown in Ap-
pendix Figure A2 (online only). Improvements in other symptoms
were also generally in favor of osimertinib, with particularly large
differences seen for nausea or vomiting and insomnia. The only
exception was for diarrhea, which improved in more patients treated
with chemotherapy than in patients treated with osimertinib.
Time to Deterioration of Symptoms and Functioning
The time to deterioration of key symptoms was prolonged
with osimertinib compared with chemotherapy, particularly for
chest pain and appetite loss (Fig 4). For the other symptoms and
functioning domains (Appendix Fig A3, online only), HRs for
deterioration were in favor of osimertinib, except for diarrhea (HR,
1.63; 95% CI, 1.19 to 2.23).
Mean Changes in Symptoms and Functioning From
Baseline
Figure 5 shows themean difference between treatment arms in
the key symptoms calculated by the mixed-effect model repeat
Patients screened
(N = 1036)
Randomly assigned
(n = 419)
Completed at baseline:
   LC13                 (n = 230)
   C30                   (n = 246)
Completed at baseline:
   LC13                    (n = 113)
   C30                      (n = 113)
Ongoing osimertinib treatment
at time of data cutoff
(n = 166)
Ongoing chemotherapy treatment
at time of data cutoff
(n = 16)
Crossed over from chemotherapy
to osimertinib by time of data cutoff
(n = 82)
Allocated to osimertinib (ITT)  (n = 279)
Received osimertinib (SAS)     (n = 279)
Allocated to chemotherapy (ITT)  (n = 140)
Received chemotherapy (SAS)     (n = 136) 
Discontinued randomized 
osimertinib treatment by
time of data cutoff
(n = 113)
Discontinued randomized 
chemotherapy treatment 
by time of data cutoff
(n = 120)
Fig 1. CONSORT diagram. C30, European Organisation for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire; ITT, intention-
to-treat; LC13, EORTC 13-item Quality of Life Questionnaire-Lung Cancer Module; SAS, safety analysis set.
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measurement. In addition, to aid clinical interpretation of the
difference between treatments at various cutoffs (eg, 10%, 15%),
Appendix Figures A4 and A5 (online only) show the cumulative
distribution changes in key symptom scores from baseline at 6 and
12 weeks, respectively. Using a cutoff of 10% or higher, significant
differences between treatment arms were observed for dyspnea,
fatigue, and appetite loss. Appendix Figure A6 (online only) shows
the mean difference between treatment arms for all functional
scales calculated by the mixed-effect model repeat measurement.
Sensitivity Analysis: Data Evaluation up to Progression
When evaluating data only up to progression, the time to
deterioration of key symptoms was longer with osimertinib than
with chemotherapy, and a greater proportion of patients reported
an improvement in global health status/quality of life, as was found
in our main analyses (Appendix Tables A1 and A2, online only).
DISCUSSION
In this study, we demonstrated that osimertinib delayed time to
deterioration of several key patient-reported symptoms in ad-
vanced NSCLC compared with chemotherapy. We also showed
a higher rate of symptom improvement with osimertinib over
chemotherapy among symptomatic patients at baseline. With an
increasing understanding of the multifaceted nature of HRQoL in
advanced cancers, time to deterioration and improvement in
symptoms and function are different but important aspects of
PROs for patients who participated in the AURA 3 trial. The PRO
data further substantiate the clinical meaningfulness of the statis-
tically significant prolongation in PFS with osimertinib over che-
motherapy. The data support regulatory approval and drug labeling
and aid physicians and patients in treatment decision making.
To the best of our knowledge, this is the first detailed study to
report on the symptom control and PRO benefits of treatment with
osimertinib. As anticipated, the sensitivity analysis that limited
PRO data up to progression was consistent with our main analyses,
which included postprogression data. However, greater effect sizes
were observed because patients randomly assigned to the che-
motherapy arm that crossed over to osimertinib at disease pro-
gression diluted the effect on the relative difference in PROs in our
main analysis.
The data from our study are comparable to that in other
trials that compared a TKI with chemotherapy. For example, in the
LUX-Lung 3 (BIBW 2992 [Afatinib] Versus Chemotherapy as First
Line Treatment in NSCLC With EGFR Mutation) trial,39 a con-
temporary study that used the same PRO instruments, afatinib was
associated with a longer time to deterioration of cough and
dyspnea but not pain when compared with chemotherapy. Physical
and role functioning, global health status/quality of life were also
improved over time with afatinib compared with chemotherapy. It
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Fig 2. PRO questionnaire completion rates
calculated as the number of evaluable forms
divided by the number of expected forms. B,
baseline; C30, European Organisation for
Research and Treatment of Cancer (EORTC)
30-item Core Quality of Life Questionnaire; D,
at discontinuation; LC13, EORTC 13-item
Quality of Life Questionnaire Lung Cancer
Module; P, at progression.
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should be noted, however, that the LUX-Lung 3 trial enrolled
treatment-naive patients whereas AURA3 enrolled previously
treated patients (second-line therapy), which further emphasizes
the effectiveness of osimertinib in controlling these key NSCLC
symptoms.
The PRO instruments are widely used in studies of advanced
NSCLC40 and have previously been well validated.32,37,41 Our
primary analysis was based on an improvement cutoff score of
$ 10% from baseline to determine clinical relevance, which is
based on observations in other cancers,38 as well as a recent meta-
analysis of multiple cancers and a variety of clinical situations.42,43
Other studies have also examined other thresholds for improve-
ment based on clinical (performance status and weight)44 and
HRQoL45 anchors in defining minimal important differences.
There were considerable variations in thresholds for the same
symptom across different studies and also for different symptoms
within the same studies. The thresholds also varied depending on
the types of anchors used. The results of differences in means of
symptoms (Fig 5) and change in function scores (Appendix Fig A6)
between treatment arms have generally reached the thresholds
considered to be minimal important differences for improvement
in the AURA 3 trial.
This analysis has several limitations. First, 82% to 88% of
patients at baseline completed the PRO questionnaires, a com-
pletion rate that is in line with that of other NSCLC clinical
trials.46,47 Second, mean absolute symptom scores were lower at
baseline in the osimertinib than in the chemotherapy arm, but
these differences were not statistically significant. Despite these
differences, the baseline scores of the osimertinib and chemo-
therapy arms of the AURA3 population were within the range of
the EORTC reference population.48 Most importantly, our analysis
focused on relative differences (rather than absolute differences),
and thus any potential imbalance in baseline scores would have
minimal effect on the results. In all of our analyses, we also adjusted
for relative differences according to the baseline PRO ratings.
Third, we did not adjust for multiple testing in our analyses.
Because PROs were a secondary end point in AURA3 and because
the trial was not powered for each of the individual PRO hy-
potheses, the results of this analysis should be considered ex-
ploratory and hypothesis-generating. Fourth, the time interval of
once every 6 weeks assessment of QLQ-C30 questionnaires might
potentially be too long to capture time to deterioration compared
with QLQ-LC13 questionnaires being assessed once per week for
the first 6 weeks. However, there is a low potential for bias because
the procedure for collecting data was similar for both treatment
arms, and consistent treatment effects were demonstrated (Fig 4)
despite differences in the assessment time points. Finally, cultural
and language factors could affect the data captured by PROs and
therefore such factors need to be considered in multinational
trials,30 although prior studies have shown that those factors made
0
Appetite loss (C30)
Fatigue (C30)
Dyspnea (LC13)
Chest pain (LC13)
Cough (LC13)
OR, 2.50 (95% CI, 1.31 to 4.84); P = .006
OR, 1.96 (95% CI, 1.20 to 3.22); P = .008
OR, 2.71 (95% CI, 1.60 to 4.38); P < .001
OR, 1.66 (95% CI, 0.83 to 3.34); P = .149
OR, 1.51 (95% CI, 0.87 to 2.61); P = .144
10 20 30
Proportion of Patients (%)
40 50 60 70
Osimertinib 80 mg (n = 279) Chemotherapy (n = 140)
n = 150
n = 84
n = 84
n = 56
n = 169
n = 89
n = 192
n = 100
n = 108
n = 60
Fig 3. Proportions of patients with improve-
ment in key lung cancer symptoms. C30, Eu-
ropean Organisation for Research and Treatment
of Cancer (EORTC) 30-item Core Quality of Life
Questionnaire; LC13, EORTC 13-item Quality of
Life Questionnaire Lung Cancer Module; OR,
odds ratio.
Table 1. Patients With Symptoms and Mean Score at Baseline
Symptom Questionnaire Treatment
Patients With
Symptoms at
Baseline*
Patients With
a Baseline Score Score at Baseline
No. % No. % Mean 95% CI
Cough LC13 Osimertinib 150 53.8 230 82.4 31.2 27.4 to 35.0
Chemotherapy 84 60.0 116 82.9 35.9 30.5 to 41.3
Chest pain LC13 Osimertinib 84 30.1 230 82.4 15.4 12.4 to 18.4
Chemotherapy 56 40.0 116 82.9 20.4 15.9 to 24.9
Dyspnea LC13 Osimertinib 169 60.6 230 82.4 22.8 20.0 to 25.6
Chemotherapy 89 63.6 116 82.9 26.6 22.4 to 30.8
Fatigue C30 Osimertinib 192 68.8 246 88.2 30.4 27.3 to 33.5
Chemotherapy 100 71.4 116 82.9 36.7 31.7 to 41.7
Appetite loss C30 Osimertinib 108 38.7 246 88.2 21.4 17.9 to 24.9
Chemotherapy 60 42.9 116 82.9 27.0 21.2 to 32.8
Abbreviations: C30, European Organisation for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire; LC13, EORTC 13-itemQuality of
Life Questionnaire-Lung Cancer Module.
*Number of patients with individual symptom scores $ 10 at baseline indicative of symptomatic status.
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only a modest contribution to the variation in PROs.49 A study of
13 different translations from 22 countries reported good linguistic
equivalence for most of the QLQ-C30 items, but several scales
showed strongly discrepant results for some translations.34 An-
other study reported that most response patterns to QLQ-C30
items were similar, but some international differences in how the
questionnaire was answered were noted, particularly for Eastern
Europeans and East Asians.34 Different cultural groups also
emphasized certain aspects of their HRQoL assessment differ-
ently.35 The potential effect of these factors is limited because our
analysis focused on the relative differences between two treatment
arms, and we also adjusted for baseline PRO ratings. Furthermore,
AURA3 was a large study in which the randomization process
resulted in a distribution between the two arms of patients who
were similar in terms of their cultural and language backgrounds.
This trial was further stratified according to Asian or non-Asian
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Fig 4. Time to symptom deterioration of key lung
cancer symptoms. C30, European Organisation for
Research and Treatment of Cancer (EORTC)
30-itemCoreQuality of LifeQuestionnaire; HR, hazard
ratio; LC13, EORTC 13-item Quality of Life Ques-
tionnaire Lung Cancer Module. NC, not calculable.
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race. Therefore, differences in these factors should not substantially
affect the conclusion of our analysis.
Prospective evaluation of PROs with the appropriate hy-
pothesis and instruments is vital, particularly in clinical trials that
evaluate new therapeutics in incurable cancers. Benefit in terms of
PROs may be expected if a drug is efficacious and has a good
tolerability profile. By contrast, if a new treatment is found to be
efficacious but highly toxic, it is impossible to evaluate the trade-off
of efficacy versus toxicity without collecting prospective PRO data.
With the increasing costs of health care, the value of new
cancer treatments is being scrutinized more closely.50 The Euro-
pean Society for Medical Oncology (ESMO) has developed and
validated the ESMO Magnitude of Clinical Benefit Scale (ESMO-
MCBS)51 for grading the magnitude of clinically meaningful
benefit. Osimertinib has been shown to improve surrogate end
points of antitumor activity, such as response rate and PFS12-14;
such a benefit would be scored as 3 of the maximum rating of 5
using the ESMO-MCBS. Because the ESMO-MCBS also empha-
sizes the effect of new treatments on global HRQoL in incurable
cancers, improvement in PROs increases the score to 4. PRO data,
as reported in our study, provide a clear contribution to evaluation
of the overall clinical benefit.
In conclusion, AURA3 demonstrated substantially improved
PROs with osimertinib when compared with chemotherapy
together with substantial improvement in PFS. These PRO data
further support the role of osimertinib as the new standard of care
in the second-line setting for patients with advanced EGFR
T790M-positive NSCLC who progressed after first-line EGFR-TKI
therapy.
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Fig A1. The proportion of patients with improvement in functioning scales. HRQoL, health-related quality of life; OR, odds ratio.
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Fig A2. The proportion of patients with improvement in remaining symptoms (other than the five key symptoms). C30, European Organisation for Research and
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Fig A3. Forest plot of hazard ratios for symptoms (other than the five key symptoms) and functioning domains.
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Fig A4. Cumulative distribution functions of absolute change in key symptom scores from baseline at 6 weeks for (A) cough, (B) chest pain, (C) dyspnea, (D) fatigue, and
(E) appetite loss.
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Table A1. Sensitivity Analysis Examining Relative Symptom Improvement Rate Between Treatment Arms from Random Assignment Until Disease Progression
Symptom No./N1 (%) OR (95% CI) RR (95% CI) Risk Difference P
Cough (LC13) Osimertinib: 91/150 (60.7) 2.06 (1.20 to 3.56) 1.42 (1.09 to 1.91) 17.8 (4.5-30.7) .009
Chemotherapy 36/84 (42.9)
Chest pain (LC13) Osimertinib: 49/84 (58.3) 2.01 (1.02 to 4.03) 1.42 (1.01 to 2.10) 17.3 (0.4-33.4) .045
Chemotherapy: 23/56 (41.1)
Dyspnoea (LC13) Osimertinib: 95/169 (56.2) 3.11 (1.81 to 5.45) 1.92 (1.39 to 2.81) 27.0 (14.6-38.6) , .001
Chemotherapy: 26/89 (29.2)
Fatigue (C30) Osimertinib: 103/192 (53.6) 2.98 (1.78 to 5.07) 1.92 (1.39 to 2.76) 25.6 (14.0-36.5) , .001
Chemotherapy: 28/100 (28.0)
Appetite loss (C30) Osimertinib: 63/108 (58.3) 3.27 (1.69 to 6.51) 1.94 (1.32 to 3.08) 28.3 (13.0-42.5) , .001
Chemotherapy: 18/60 (30.0)
NOTE. An OR or RR . 1 or a risk difference . 0 favors osimertinib.
Abbreviations: C30; European Organisation for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire; LC13; European Organisation for
Research and Treatment of Cancer 13-Item Quality of Life Questionnaire-Lung Cancer Module; No., number of patients with improvement; N1, number of patients with
symptom scales baseline individual scores $ 10; RR, relative risk. OR, odd ratio; RR, relative risk.
Table A2. Sensitivity Analysis Examining Relative Time to Symptom Deterioration Between Treatment Arms From Random Assignment Until Disease Progression
Symptom No./N1 (%) HR (95% CI) P Median Time to Deterioration (months)
Cough (LC13) Osimertinib: 89/215 (41.4) 0.68 (0.48 to 0.96) .028 12.42 (6.28-NC)
Chemotherapy: 52/106 (49.1) 3.38 (0.99-NC)
Chest pain (LC13) Osimertinib: 83/226 (36.7) 0.48 (0.34 to 0.67) , .001 12.42 (9.66-NC)
Chemotherapy: 61/113 (54.0) 2.27 (0.89-5.45)
Dyspnoea (LC13) Osimertinib: 112/228 (49.1) 0.44 (0.32 to 0.59) , .001 6.21 (4.76-9.69)
Chemotherapy: 77/114 (67.5) 0.56 (0.43-0.99)
Fatigue (C30) Osimertinib: 115/242 (47.5) 0.63 (0.46 to 0.88) .008 6.83 (4.21-11.17)
Chemotherapy: 54/110 (49.1) 2.69 (1.45-5.68)
Appetite loss (C30) Osimertinib: 79/237 (33.3) 0.45 (0.32 to 0.65) , .001 NC (9.63-NC)
Chemotherapy: 50/107 (46.7) 4.27 (2.79-6.87)
NOTE. A hazard ratio , 1 favors osimertinib.
Abbreviations: HR, hazard ratio; LC13; European Organisation for Research and Treatment of Cancer 13-Item Quality of Life Questionnaire-Lung Cancer Module; No.,
number of patients with deterioration; N1, number of patients who have baseline individual score # 90; NC, Noncalculable.
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